Completion of the pivotal phase 3 trial for olanzapine LAI in schizophrenia conducted by Teva Pharmaceuticals
- Teva Pharmaceuticals has completed a pivotal Phase 3 trial for olanzapine long-acting injectable (LAI) in patients with schizophrenia.
- The trial aimed to evaluate the efficacy and safety of olanzapine LAI in managing symptoms of schizophrenia.
- Results from the trial will be used to support regulatory submissions in various regions.
- Next steps include analyzing the trial data and preparing for potential regulatory filings.
Read more
Yaqrit prepares phase 3 for ammonia scavenger in hepatic encephalopathy
- Yaqrit is advancing L-ornithine phenylacetate (OPA) to phase 3 for acute hepatic encephalopathy treatment.
- The IV formulation will enter phase 3, while the oral formulation will start phase 2b trials for HE prevention.
- Yaqrit acquired global rights for OPA from Mallinckrodt Pharmaceuticals, with milestone payments and royalties involved.
- OPA has shown potential in reducing toxic ammonia levels, crucial for patients with advanced liver disease.
Read more
Ashvattha presents positive phase 2 data for subcutaneous migaldendranib
- Phase 2 study of Migaldendranib (MGB) shows promising results for wet AMD and DME.
- Subcutaneous MGB reduces anti-VEGF treatment burden by over 69% in study eyes.
- Maintains central subfield thickness and visual acuity in treated patients.
- Safe and well-tolerated with no treatment-related ocular adverse events reported.
Read more
